These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
580 related articles for article (PubMed ID: 8594268)
21. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella. Tischer A; Gerike E Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of mumps antibodies after measles-mumps-rubella (MMR) vaccines. Ozaki K; Kuno-Sakai H; Kimura M Tokai J Exp Clin Med; 1987 Dec; 12(5-6):305-11. PubMed ID: 3508655 [TBL] [Abstract][Full Text] [Related]
23. Evaluation of a combined vaccine against measles-mumps-rubella produced on human diploid cells. Just M; Berger R; Glück R; Wegmann A Dev Biol Stand; 1986; 65():25-7. PubMed ID: 3549399 [TBL] [Abstract][Full Text] [Related]
24. [Drug clinics. Drug of the month. A new measles-rubella-mumps vaccine (Priorix)]. Senterre J Rev Med Liege; 1999 Feb; 54(2):122-4. PubMed ID: 10221066 [TBL] [Abstract][Full Text] [Related]
25. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age. Gatchalian S; Cordero-Yap L; Lu-Fong M; Soriano R; Ludan A; Chitour K; Bock HL Southeast Asian J Trop Med Public Health; 1999 Sep; 30(3):511-7. PubMed ID: 10774661 [TBL] [Abstract][Full Text] [Related]
26. Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland. Davidkin I; Peltola H; Leinikki P; Valle M Vaccine; 2000 Jul; 18(27):3106-12. PubMed ID: 10856790 [TBL] [Abstract][Full Text] [Related]
27. Measles, mumps, rubella antibody surveillance: pilot study in Grampian, Scotland. Narayan KM; Moffat MA Health Bull (Edinb); 1992 Jan; 50(1):47-53. PubMed ID: 1612895 [TBL] [Abstract][Full Text] [Related]
28. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines. Miller E; Hill A; Morgan-Capner P; Forsey T; Rush M Vaccine; 1995 Jun; 13(9):799-802. PubMed ID: 7483800 [TBL] [Abstract][Full Text] [Related]
29. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). Watson JC; Hadler SC; Dykewicz CA; Reef S; Phillips L MMWR Recomm Rep; 1998 May; 47(RR-8):1-57. PubMed ID: 9639369 [TBL] [Abstract][Full Text] [Related]
30. Response to measles-mumps-rubella vaccine in children on dialysis. Schulman SL; Deforest A; Kaiser BA; Polinsky MS; Baluarte HJ Pediatr Nephrol; 1992 Mar; 6(2):187-9. PubMed ID: 1571219 [TBL] [Abstract][Full Text] [Related]
31. A search for persistent measles, mumps, and rubella vaccine virus in children with human immunodeficiency virus type 1 infection. Frenkel LM; Nielsen K; Garakian A; Cherry JD Arch Pediatr Adolesc Med; 1994 Jan; 148(1):57-60. PubMed ID: 8143011 [TBL] [Abstract][Full Text] [Related]
32. Measles, mumps, and rubella antibodies in vaccinated Baltimore children. King JC; Lichenstein R; Feigelman S; Luna C; Permutt TJ; Patel J Am J Dis Child; 1993 May; 147(5):558-60. PubMed ID: 8488803 [TBL] [Abstract][Full Text] [Related]
33. Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age. Klinge J; Lugauer S; Korn K; Heininger U; Stehr K Vaccine; 2000 Jul; 18(27):3134-40. PubMed ID: 10856793 [TBL] [Abstract][Full Text] [Related]
34. Effect of simultaneous administration of live measles vaccine on the "take rate" of live mumps vaccine. André FE; Peetermans J Dev Biol Stand; 1986; 65():101-7. PubMed ID: 3556770 [TBL] [Abstract][Full Text] [Related]
35. [Mumps epidemic in vaccinated children in West Switzerland]. Ströhle A; Eggenberger K; Steiner CA; Matter L; Germann D Schweiz Med Wochenschr; 1997 Jun; 127(26):1124-33. PubMed ID: 9312835 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of a two-dose measles, mumps, and rubella vaccination schedule in a cohort of college athletes. Coté TR; Sivertson D; Horan JM; Lindegren ML; Dwyer DM Public Health Rep; 1993; 108(4):431-5. PubMed ID: 8341775 [TBL] [Abstract][Full Text] [Related]
37. Simultaneous administration of a diphtheria and tetanus toxoids and acellular pertussis vaccine with measles-mumps-rubella and oral poliovirus vaccines. Rothstein EP; Bernstein HH; Glode MP; Laussucq S; Nonenmacher J; Long SS; Hackell JG Am J Dis Child; 1993 Aug; 147(8):854-7. PubMed ID: 8394646 [TBL] [Abstract][Full Text] [Related]
38. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children. Usonis V; Bakasenas V; Kaufhold A; Chitour K; Clemens R Pediatr Infect Dis J; 1999 Jan; 18(1):42-8. PubMed ID: 9951979 [TBL] [Abstract][Full Text] [Related]
39. A second dose of MMR vaccine for children in the United Kingdom. Commun Dis Rep CDR Wkly; 1996 Jul; 6(30):259. PubMed ID: 8755703 [No Abstract] [Full Text] [Related]
40. Gender differences in the reactogenicity of measles-mumps-rubella vaccine. Shohat T; Green MS; Nakar O; Ballin A; Duvdevani P; Cohen A; Shohat M Isr Med Assoc J; 2000 Mar; 2(3):192-5. PubMed ID: 10774264 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]